BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 28071724)

  • 1. Osteoclastic miR-214 targets TRAF3 to contribute to osteolytic bone metastasis of breast cancer.
    Liu J; Li D; Dang L; Liang C; Guo B; Lu C; He X; Cheung HY; He B; Liu B; Li F; Lu J; Wang L; Shaikh AB; Jiang F; Lu C; Peng S; Zhang Z; Zhang BT; Pan X; Xiao L; Lu A; Zhang G
    Sci Rep; 2017 Jan; 7():40487. PubMed ID: 28071724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR-346-3p promotes osteoclastogenesis via inhibiting TRAF3 gene.
    Mao Y; Chen Y; Fu Y; Guan J; Liang M; Zhu Y; Yang F; Li F; Zhang Z; Wan C; Zhou P
    In Vitro Cell Dev Biol Anim; 2020 Aug; 56(7):533-542. PubMed ID: 32839904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small extracellular vesicles deliver osteolytic effectors and mediate cancer-induced osteolysis in bone metastatic niche.
    Ma Q; Liang M; Wu Y; Dou C; Xu J; Dong S; Luo F
    J Extracell Vesicles; 2021 Feb; 10(4):e12068. PubMed ID: 33659051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory roles of miRNAs 16, 133a, and 223 on osteoclastic bone destruction caused by breast cancer metastasis.
    Kitayama K; Kawamoto T; Kawakami Y; Hara H; Takemori T; Fujiwara S; Yahiro S; Miyamoto T; Mifune Y; Hoshino Y; Kakutani K; Matsumoto T; Matsushita T; Niikura T; Kuroda R; Akisue T
    Int J Oncol; 2021 Nov; 59(5):. PubMed ID: 34713296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation.
    Li D; Liu J; Guo B; Liang C; Dang L; Lu C; He X; Cheung HY; Xu L; Lu C; He B; Liu B; Shaikh AB; Li F; Wang L; Yang Z; Au DW; Peng S; Zhang Z; Zhang BT; Pan X; Qian A; Shang P; Xiao L; Jiang B; Wong CK; Xu J; Bian Z; Liang Z; Guo DA; Zhu H; Tan W; Lu A; Zhang G
    Nat Commun; 2016 Mar; 7():10872. PubMed ID: 26947250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption.
    Sasaki A; Alcalde RE; Nishiyama A; Lim DD; Mese H; Akedo H; Matsumura T
    Cancer Res; 1998 Feb; 58(3):462-7. PubMed ID: 9458090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MMP-13 stimulates osteoclast differentiation and activation in tumour breast bone metastases.
    Pivetta E; Scapolan M; Pecolo M; Wassermann B; Abu-Rumeileh I; Balestreri L; Borsatti E; Tripodo C; Colombatti A; Spessotto P
    Breast Cancer Res; 2011 Oct; 13(5):R105. PubMed ID: 22032644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gallium, a promising candidate to disrupt the vicious cycle driving osteolytic metastases.
    Strazic-Geljic I; Guberovic I; Didak B; Schmid-Antomarchi H; Schmid-Alliana A; Boukhechba F; Bouler JM; Scimeca JC; Verron E
    Biochem Pharmacol; 2016 Sep; 116():11-21. PubMed ID: 27378505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-338-3p inhibits glucocorticoid-induced osteoclast formation through RANKL targeting.
    Zhang XH; Geng GL; Su B; Liang CP; Wang F; Bao JC
    Genet Mol Res; 2016 Aug; 15(3):. PubMed ID: 27706599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2.
    Krzeszinski JY; Wei W; Huynh H; Jin Z; Wang X; Chang TC; Xie XJ; He L; Mangala LS; Lopez-Berestein G; Sood AK; Mendell JT; Wan Y
    Nature; 2014 Aug; 512(7515):431-5. PubMed ID: 25043055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway.
    Bendre MS; Margulies AG; Walser B; Akel NS; Bhattacharrya S; Skinner RA; Swain F; Ramani V; Mohammad KS; Wessner LL; Martinez A; Guise TA; Chirgwin JM; Gaddy D; Suva LJ
    Cancer Res; 2005 Dec; 65(23):11001-9. PubMed ID: 16322249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human breast cancer induces osteoclast activation and increases the number of osteoclasts at sites of tumor osteolysis.
    Clohisy DR; Palkert D; Ramnaraine ML; Pekurovsky I; Oursler MJ
    J Orthop Res; 1996 May; 14(3):396-402. PubMed ID: 8676252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical evaluation of zoledronate using an in vitro mimetic cellular model for breast cancer metastatic bone disease.
    Dedes PG; Kanakis I; Gialeli Ch; Theocharis AD; Tsegenidis T; Kletsas D; Tzanakakis GN; Karamanos NK
    Biochim Biophys Acta; 2013 Jun; 1830(6):3625-34. PubMed ID: 23395844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-derived miR-378a-3p-containing extracellular vesicles promote osteolysis by activating the Dyrk1a/Nfatc1/Angptl2 axis for bone metastasis.
    Wang J; Du X; Wang X; Xiao H; Jing N; Xue W; Dong B; Gao WQ; Fang YX
    Cancer Lett; 2022 Feb; 526():76-90. PubMed ID: 34801597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hedgehog signaling induced by breast cancer cells promotes osteoclastogenesis and osteolysis.
    Das S; Samant RS; Shevde LA
    J Biol Chem; 2011 Mar; 286(11):9612-22. PubMed ID: 21169638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-325-3p, a novel regulator of osteoclastogenesis in osteolysis of colorectal cancer through targeting S100A4.
    Chengling L; Yulin Z; Xiaoyu X; Xingchen L; Sen Z; Ziming W; Xianming C
    Mol Med; 2021 Mar; 27(1):23. PubMed ID: 33691630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease.
    Bendre MS; Montague DC; Peery T; Akel NS; Gaddy D; Suva LJ
    Bone; 2003 Jul; 33(1):28-37. PubMed ID: 12919697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-29b-3p promotes progression of MDA-MB-231 triple-negative breast cancer cells through downregulating TRAF3.
    Zhang B; Shetti D; Fan C; Wei K
    Biol Res; 2019 Jul; 52(1):38. PubMed ID: 31349873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alexidine Dihydrochloride Attenuates Osteoclast Formation and Bone Resorption and Protects Against LPS-Induced Osteolysis.
    Zhu X; Gao J; Ng PY; Qin A; Steer JH; Pavlos NJ; Zheng MH; Dong Y; Cheng TS
    J Bone Miner Res; 2016 Mar; 31(3):560-72. PubMed ID: 26363136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tie2 signaling regulates osteoclastogenesis and osteolytic bone invasion of breast cancer.
    Min Y; Ren X; Vaught DB; Chen J; Donnelly E; Lynch CC; Lin PC
    Cancer Res; 2010 Apr; 70(7):2819-28. PubMed ID: 20233869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.